The Anticoagulant Properties of a Modified Form of Protein S

Summary

Protein S (PS) is a vitamin K-dependent anticoagulant that acts as a cofactor to activated protein C (APC). To date PS has not been shown to possess anticoagulant activity in the absence of APC.

In this study, we have developed monoclonal antibody to protein S and used to purify the protein to homogeneity from plasma. Affinity purified protein S (PSM), although identical to the conventionally purified protein as judged by SDS-PAGE, had significant anticoagulant activity in the absence of APC when measured in a factor X_a recalcification time. Using SDS-PAGE we have demonstrated that prothrombin cleavage by factor X _awas inhibited in the presence of PSM. Kinetic analysis of the reaction revealed that PSM competitively inhibited factor X _amediated cleavage of prothrombin. PS preincubated with the monoclonal antibody, acquired similar anticoagulant properties. These results suggest that the interaction of the monoclonal antibody with PS results in an alteration in the protein exposing sites that mediate the observed anticoagulant effect. Support that the protein was altered was derived from the observation that PSM was eight fold more sensitive to cleavage by thrombin and human neutrophil elastase than conventionally purified protein S.

These observations suggest that PS can be modified in vitro to a protein with APC-independent anticoagulant activity and raise the possibility that a similar alteration could occur in vivo through the binding protein S to a cellular or plasma protein.

Keywords

Protein S - Thrombosis - Coagulation

• References

• 1 Walker FJ. Regulation of activated protein C by a new protein. J Biol Chem 1980; 255: 5521-5524
• 2 Walker FJ, Sexton PW, Esmon CT. The inhibition of blood coagulation by activated protein C through the selective inactivation of activated factor V. Biochim Biophys Acta 1979; 571: 333-342
• 3 Walker FJ. Regulation of activated protein C by protein S. The role of phospholipid in factor V_a inactivation. J Biol Chem 1981; 256: 11128-11131
• 4 Harris K, Esmon CT. Protein S is required for bovine platelets to support activated protein C binding and activity. J Biol Chem 1985; 260: 2007-2010
• 5 Griffin JH, Evatt B, Zimmerman TS, Kleiss AJ, Wideman C. Deficiency of protein C in congenital thrombotic disease. J Clin Invest 1981; 68: 1370-1373
• 6 Comp P, Esmon CT. Recurrent venous thromboembolism in a patient with partial deficiency of protein S. N Engl J Med 1984; 311: 1525-1528
• 7 Dahlback B, Lundwall A, Stenflo J. Primary structure of bovine vitamin K dependent protein S. Proc Natl Acad Sci (USA) 1986; 83: 4199-4203
• 8 Mitchell CA, Hau L, Salem HH. Control of thrombin mediated cleavage of protein S. Thromb Haemostas 1986; 56: 151-154
• 9 Dahlback B. Purification of vitamin K dependent protein S and its limited proteolysis by thrombin. Biochem J 1983; 209: 2007-2010
• 10 Salem HH, Esmon NL, Esmon CT, Majerus PW. Effect of thrombomodulin and factor V_a light chain on protein C activation in vitro. J Clin Invest 1984; 73: 968-972
• 11 Miletich JP, Broze GJ, Majerus PW. The synthesis of sulphated dextran beads for the isolation of human coagulation factors II, IX and X. Anal Biochem 1980; 105: 304-310
• 12 Miletich JP, Jackson CM, Majerus PW. Properties of the factor X_a binding site on human platelets. J Biol Chem 1978; 253: 6908-6916
• 13 Kane WH, Majerus PW. Purification and characterization of human coagulation factor V. J Biol Chem 1981; 256: 1002-1007
• 14 Jakobsen E, Kierulf P. A modified beta alanine precipitation procedure to prepare fibrinogen free of antithrombin III and plasminogen. Thromb Res 1973; 3: 145-159
• 15 McEver RP, Baenziger NL, Majerus PW. Isolation and quantition of the platelet membrane glycoprotein deficient in thrombasthenia using a monoclonal hybridoma technique. J Clin Invest 1980; 66: 1311-1318
• 16 Kohn J, Wilchek M. A new approach for cyanogen bromide activation of separose at neutral pH, which yields activated resins, free of interfering nitrogen derivatives. Biochim Biophys Res Commun 1982; 107: 878-884
• 17 Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685
• 18 Miletich JP, Majerus DW, Majerus PW. Patients with congenital factor V deficiency have decreased factor X_a binding sites on their platelets. J Clin Invest 1978; 62: 826-831
• 19 Mitchell CA, Salem HH. The cleavage of protein S by a platelet membrane protease. J Clin Invest 1987; 79: 374-379
• 20 Maruyama I, Majerus PW. The turnover of thrombin-thrombomodulin complex in cultured human umbilical vein endothelial cells and A549 lung cancer cells. J Biol Chem 1985; 260: 15432-15438
• 21 Walker FJ. Identification of a new protein involved in the regulation of the anticoagulant activity of activated protein C. J Biol Chem 1986; 261: 10941-10944